157 related articles for article (PubMed ID: 19208585)
1. Blockade of interleukin 6 signaling induces marked neutropenia in patients with rheumatoid arthritis.
Nakamura I; Omata Y; Naito M; Ito K
J Rheumatol; 2009 Feb; 36(2):459-60. PubMed ID: 19208585
[No Abstract] [Full Text] [Related]
2. Inhibiting interleukin-6 in rheumatoid arthritis.
Choy E
Curr Rheumatol Rep; 2008 Oct; 10(5):413-7. PubMed ID: 18817647
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapeutic implication of IL-6 blockade.
Tanaka T; Kishimoto T
Immunotherapy; 2012 Jan; 4(1):87-105. PubMed ID: 22150003
[TBL] [Abstract][Full Text] [Related]
4. Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo.
Wright HL; Cross AL; Edwards SW; Moots RJ
Rheumatology (Oxford); 2014 Jul; 53(7):1321-31. PubMed ID: 24609058
[TBL] [Abstract][Full Text] [Related]
5. Serious herpes zoster in rheumatoid arthritis under anti-interleukin-6 receptor antibody.
Kubandova Z; Mathieu S; Pourtier C; Soubrier M
Joint Bone Spine; 2010 Dec; 77(6):623-4. PubMed ID: 20851657
[No Abstract] [Full Text] [Related]
6. Interrupting tocilizumab therapy-induced psoriasis-like eruption in a patient with rheumatoid arthritis and Crohn's disease.
Saito Y; Hayashi S; Gonmori T; Hamasaki Y; Igawa K
Int J Dermatol; 2020 May; 59(5):e159-e160. PubMed ID: 32034760
[No Abstract] [Full Text] [Related]
7. Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration.
Drucker C; Gewiese J; Malchow S; Scheller J; Rose-John S
J Autoimmun; 2010 Feb; 34(1):29-37. PubMed ID: 19717281
[TBL] [Abstract][Full Text] [Related]
8. Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders.
Paul-Pletzer K
Drugs Today (Barc); 2006 Sep; 42(9):559-76. PubMed ID: 17028666
[TBL] [Abstract][Full Text] [Related]
9. [Humanized anti-human IL-6 receptor antibody, tocilizumab].
Nishimoto N
Nihon Rinsho; 2007 Jul; 65(7):1218-25. PubMed ID: 17642235
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-6 in the pathogenesis of rheumatoid arthritis.
Park JY; Pillinger MH
Bull NYU Hosp Jt Dis; 2007; 65 Suppl 1():S4-10. PubMed ID: 17708744
[TBL] [Abstract][Full Text] [Related]
11. [Tocilizumab in rheumatoid arthritis. Interleukin 6 as a new target].
Heinzl S
Med Monatsschr Pharm; 2008 Dec; 31(12):450-3. PubMed ID: 19133593
[No Abstract] [Full Text] [Related]
12. Interleukin-6 as a key player in systemic inflammation and joint destruction.
Fonseca JE; Santos MJ; Canhão H; Choy E
Autoimmun Rev; 2009 Jun; 8(7):538-42. PubMed ID: 19189867
[TBL] [Abstract][Full Text] [Related]
13. Is interleukin-6 receptor blockade the Holy Grail for inflammatory diseases?
Febbraio MA; Rose-John S; Pedersen BK
Clin Pharmacol Ther; 2010 Apr; 87(4):396-8. PubMed ID: 20305672
[TBL] [Abstract][Full Text] [Related]
14. Neuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritis.
Choy EHS; Calabrese LH
Rheumatology (Oxford); 2018 Nov; 57(11):1885-1895. PubMed ID: 29186541
[TBL] [Abstract][Full Text] [Related]
15. Interlukin-6 receptor inhibitor tocilizumab: a new treatment option in rheumatoid arthritis?
Johnson J; Wang MY
Neurosurgery; 2008 Aug; 63(2):N8. PubMed ID: 18797345
[No Abstract] [Full Text] [Related]
16. Exacerbation of chronic active Epstein-Barr virus infection in a patient with rheumatoid arthritis receiving humanised anti-interleukin-6 receptor monoclonal antibody.
Ogawa J; Harigai M; Akashi T; Nagasaka K; Suzuki F; Tominaga S; Miyasaka N
Ann Rheum Dis; 2006 Dec; 65(12):1667-9. PubMed ID: 17105857
[No Abstract] [Full Text] [Related]
17. Immediate reduction of white blood cell count after tocilizumab administration was observed in some cases.
Nagamine R; Chen W; Hara T; Kondo K; Sugioka Y
Mod Rheumatol; 2009; 19(3):348-50. PubMed ID: 19288171
[No Abstract] [Full Text] [Related]
18. Drug eruption induced by IL-6 receptor inhibitor tocilizumab.
Yoshiki R; Nakamura M; Tokura Y
J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):495-6. PubMed ID: 19754658
[No Abstract] [Full Text] [Related]
19. Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody.
Yoshizaki K; Nishimoto N; Mihara M; Kishimoto T
Springer Semin Immunopathol; 1998; 20(1-2):247-59. PubMed ID: 9836380
[No Abstract] [Full Text] [Related]
20. Linking interleukin-6 receptor blockade with tocilizumab and its hematological effects using a modeling approach.
Gibiansky L; Frey N
J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):5-16. PubMed ID: 22101760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
